Security
FATE · FATE THERAPEUTICS INC
FATENASDAQCommon stockCurrentCIK 1434316Updated Sep 27, 2026
FATE price & chart
Loading TradingView…
NASDAQ:FATE on TradingView ↗About the company
Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications.
In the news
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference ↗
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them ↗
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment News provided by USA News Group Aug 14, 2025, 12:22 ET Share this article Share to X Share this article Share to X USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Aug. 14, 2025 /PRNew ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 318,937,000Source | 440,694,000Source | 506,217,000Source | 705,561,000Source |
| Property, Plant and Equipment, NetUSD | 56,925,000Source | 64,384,000Source | 96,836,000Source | 110,020,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 46,628,000Source | 36,056,000Source | 41,870,000Source | 61,333,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 916,000Source | 3,539,000Source | 1,826,000Source | 38,480,000Source |
| Assets, CurrentUSD | 208,704,000Source | 291,909,000Source | 331,540,000Source | 502,074,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,131,000Source | 9,302,000Source | 14,539,000Source | 27,367,000Source |
| Operating Lease, Right-of-Use AssetUSD | 41,609,000Source | 46,508,000Source | 61,675,000Source | 66,069,000Source |
| Other Assets, NoncurrentUSD | 0Source | 9,000Source | 9,000Source | 33,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 3,000Source | 3,000Source | 3,000Source | 3,000Source |
| Common Stock, Value, IssuedUSD | 115,000Source | 114,000Source | 99,000Source | 97,000Source |
| Additional Paid in CapitalUSD | 1,741,259,000Source | 1,716,335,000Source | 1,580,032,000Source | 1,536,497,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,534,309,000Source | -1,397,994,000Source | -1,211,732,000Source | -1,050,804,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 116,000Source | 268,000Source | 15,000Source | -1,854,000Source |
| Stockholders' Equity Attributable to ParentUSD | 207,184,000Source | 318,726,000Source | 368,417,000Source | 483,939,000Source |
| Liabilities and EquityUSD | 318,937,000Source | 440,694,000Source | 506,217,000Source | 705,561,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 36,071,000Source | 38,522,000Source | 39,094,000Source | 114,051,000Source |
| Operating Lease, Liability, CurrentUSD | 4,562,000Source | 7,416,000Source | 6,176,000Source | 5,628,000Source |
| Accounts Payable, CurrentUSD | 2,656,000Source | 9,365,000Source | 4,719,000Source | 8,265,000Source |
| Operating Lease, Liability, NoncurrentUSD | 73,287,000Source | 77,849,000Source | 97,360,000Source | 103,710,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 20,024,000Source | 21,348,000Source | 27,514,000Source | 53,932,000Source |
| Deferred Tax Liabilities, NetUSD | 387,974,000Source | 362,084,000Source | 323,962,000Source | 296,247,000Source |
| Short-term InvestmentsUSD | 157,029,000Source | 243,012,000Source | 273,305,000Source | 374,894,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -136,315,000Source | -186,262,000Source | -160,928,000Source | -281,721,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 12,901,000Source | 18,962,000Source | 18,282,000Source | 13,758,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -2,624,000Source | 1,113,000Source | -36,654,000Source | 29,804,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -106,084,000Source | -122,874,000Source | -132,263,000Source | -248,208,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 111,166,000Source | 12,218,000Source | 112,665,000Source | 166,751,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,953,000Source | 730,000Source | 6,153,000Source | 35,566,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,490,000Source | 99,892,000Source | 85,000Source | 9,207,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 10,572,000Source | -10,764,000Source | -19,513,000Source | -72,250,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 1,600Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 24,924,000Source | 41,496,000Source | 43,459,000Source | 78,733,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -9,000Source | -942,000Source | — | — |
| General and Administrative ExpenseUSD | 46,521,000Source | 74,169,000Source | 81,448,000Source | 84,232,000Source |
| Income Tax Expense (Benefit)USD | 2,000Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 11,052,000Source | 17,288,000Source | 17,186,000Source | 5,842,000Source |
| Net Income (Loss) Attributable to ParentUSD | -136,315,000Source | -186,262,000Source | -160,928,000Source | -281,721,000Source |
| Operating ExpensesUSD | 154,350,000Source | 223,907,000Source | 254,044,000Source | 404,686,000Source |
| Other Nonoperating Income (Expense)USD | 11,389,000Source | 24,014,000Source | 29,583,000Source | 26,665,000Source |
| Payments to Acquire InvestmentsUSD | 195,143,000Source | 317,750,000Source | 358,810,000Source | 404,796,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 295,000Source | 85,000Source | 9,207,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 6,646,000Source | 13,631,000Source | 63,533,000Source | 96,300,000Source |
| Operating Income (Loss)USD | -147,704,000Source | -210,276,000Source | -190,511,000Source | -308,386,000Source |
| Other Nonoperating Income (Expense)USD | 11,389,000Source | 24,014,000Source | 29,583,000Source | 26,665,000Source |
| Income Tax Expense (Benefit)USD | 2,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -136,315,000Source | -186,262,000Source | -160,928,000Source | -281,721,000Source |
| Earnings Per Share, BasicUSD per share | -1.15Source | -1.64Source | -1.64Source | -2.91Source |
| Earnings Per Share, DilutedUSD per share | -1.15Source | -1.64Source | -1.64Source | -2.91Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 118,789,974Source | 113,685,177Source | 98,411,162Source | 96,826,058Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 118,789,974Source | 113,685,177Source | 98,411,162Source | 96,826,058Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 46,521,000Source | 74,169,000Source | 81,448,000Source | 84,232,000Source |
| Investment Income, InterestUSD | 11,052,000Source | 17,288,000Source | 17,186,000Source | 5,842,000Source |
| Operating ExpensesUSD | 154,350,000Source | 223,907,000Source | 254,044,000Source | 404,686,000Source |
| Other General and Administrative ExpenseUSD | — | — | 2,000,000Source | — |
| Research and Development ExpenseUSD | 107,829,000Source | 135,001,000Source | 172,596,000Source | 320,454,000Source |
Filing attachments
fate-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 fate-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge FDA clearance of the FT839 IND application advances the Company’s novel dual CD19/CD38 targeting off-the-shelf CAR T-cell product…
Read attachment ↗d83385dex991.htm · 8-K · 2026-06-04
EX-99.1 2 d83385dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies Accessible to AllTM CORPORATE PRESENTATION June 2026 | NASDAQ: FATE | Non-Confidential © 2026 Fate Therapeutics. All rights reserved Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety …
Read attachment ↗fate-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 fate-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates RECLAIM - LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with t…
Read attachment ↗fate-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 fate-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluat…
Read attachment ↗fate-ex99_1.htm · 8-K · 2025-11-13
EX-99.1 2 fate-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Conditioning, Enabling Broad Patient Accessibility First Systemic Sclerosis Patient treated in Phase 1 Study of FT819…
Read attachment ↗d36426dex991.htm · 8-K · 2025-10-27
EX-99.1 2 d36426dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioni…
Read attachment ↗